Cargando…

Genome-Wide Data reveals Novel Genes for Methotrexate Response in a Large Cohort of Juvenile Idiopathic Arthritis Cases

Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to targeted treatment. We genotyped 759 JIA cases fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cobb, Joanna, Cule, Erika, Moncrieffe, Halima, Hinks, Anne, Ursu, Simona, Patrick, Fiona, Kassoumeri, Laura, Flynn, Edward, Bulatović, Maja, Wulffraat, Nico, van Zelst, Bertrand, de Jonge, Robert, Bohm, Marek, Dolezalova, Pavla, Hirani, Shashi, Newman, Stanton, Whitworth, Pamela, Southwood, Taunton R, De Iorio, Maria, Wedderburn, Lucy R, Thomson, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091986/ https://www.ncbi.nlm.nih.gov/pubmed/24709693 http://dx.doi.org/10.1038/tpj.2014.3

Ejemplares similares

Methotrexate in childhood arthritis: effects on gene expression
por: Moncrieffe, H, et al.
Publicado: (2008)

Mothers’ reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life
por: Mulligan, Kathleen, et al.
Publicado: (2013)

Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis
por: Hinks, Anne, et al.
Publicado: (2011)

Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
por: Moncrieffe, H, et al.
Publicado: (2011)

Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
por: Ursu, S, et al.
Publicado: (2011)

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
por: Hirani, SP, et al.
Publicado: (2008)

Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA)
por: Hirani, SP, et al.
Publicado: (2008)

Correlation of Low CD73 Expression on Synovial Lymphocytes With Reduced Adenosine Generation and Higher Disease Severity in Juvenile Idiopathic Arthritis
por: Botta Gordon‐Smith, Sophie, et al.
Publicado: (2015)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, EH Pieter, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

PReS-FINAL-2162: Development of a risk model to predict methotrexate intolerance in juvenile idiopathic arthritis
por: Van Dijkhuizen, P, et al.
Publicado: (2013)

PReS-FINAL-1001: Lymphocytes from the inflamed joint of juvenile idiopathic arthritis patients express reduced levels of cd73 and have a functional defect in adenosine production
por: Botta Gordon-Smith, S, et al.
Publicado: (2013)

Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis
por: Omoyinmi, Ebun, et al.
Publicado: (2012)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study
por: van Dijkhuizen, Evert Hendrik Pieter, et al.
Publicado: (2015)

PReS-FINAL-1017: Antioxidant superoxide dismutase activity is elevated in jia but not associated with disease activity
por: Radziszewska, A, et al.
Publicado: (2013)

PReS-FINAL-1009: Antioxidant superoxide dismutase activity is paradoxically normal in juvenile systemic lupus erythematosus
por: Radziszewska, A, et al.
Publicado: (2013)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

Share – Workpackage 4: addressing the need for health care for paediatric rheumatic diseases throughout europe
por: Dolezalova, Pavla, et al.
Publicado: (2014)

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013)

The transcription factor crem-αlpha regulates inflammatory T cell subsets in juvenile idiopathic arthritis
por: Ohl, Kim, et al.
Publicado: (2014)

Paediatric Teaching: Core Paediatric Conditions
por: Southwood, Taunton
Publicado: (1996)

The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people
por: Mulligan, Kathleen, et al.
Publicado: (2015)

Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis
por: de Rotte, Maurits C. F. J., et al.
Publicado: (2018)

Interleukin-17–producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers
por: Nistala, Kiran, et al.
Publicado: (2008)

Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis
por: van de Meeberg, Maartje M., et al.
Publicado: (2022)

Association of SLCO1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients
por: Ramsey, Laura B., et al.
Publicado: (2019)

Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

PFAPA syndrome in the Czech Republic: a single-centre experience
por: Król, Petra, et al.
Publicado: (2012)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

Evaluation of an nhs juvenile idiopathic arthritis (JIA) treatment pathway compared to published international recommendations
por: Green, Katherone L, et al.
Publicado: (2014)

Vasculitis
por: Dolezalova, Pavla
Publicado: (2014)

Are parents' views about their child's treatment for juvenile idiopathic arthritis (JIA) related to evaluations of their child's quality of life (QoL)? – SPARKS CHARM study
por: Mulligan, K, et al.
Publicado: (2008)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

The Effects of a Web-Based Tool for Parents of Children With Juvenile Idiopathic Arthritis: Randomized Controlled Trial
por: Mulligan, Kathleen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m879a0nog02qli1dfhcfqbm03e